comparemela.com

Latest Breaking News On - One biopharmaceuticals - Page 1 : comparemela.com

Day One Announces Sale of Priority Review Voucher for $108 Million

Day One Announces Sale of Priority Review Voucher for $108 Million
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Brisbane
Queensland
Australia
California
United-states
Laura-cooper
Linkedin
Head-of-communications
Drug-administration
Exchange-commission
Viracta-therapeutics-inc
Rare-pediatric-disease-priority-review-voucher-program

Day One Announces Sale of Priority Review Voucher for $108

Day One Announces Sale of Priority Review Voucher for $108
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Brisbane
Queensland
Australia
California
United-states
Laura-cooper
Linkedin
Exchange-commission
Drug-administration
Head-of-communications
Viracta-therapeutics-inc
Rare-pediatric-disease-priority-review-voucher-program

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Franklin Resources Inc.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Franklin Resources Inc.
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

China
Samuelc-blackman
Piper-sandler
Dynamic-technology-lab-private-ltd
Goldman-sachs-group
China-universal-asset-management-co
Exchange-commission
Securities-exchange-commission
Day-one-biopharmaceuticals-inc
Jpmorgan-chase-co
Franklin-resources-inc
Quest-partners

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Rating of "Moderate Buy" from Analysts

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) has received a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 […]

China
Jeremy-bender
Piper-sandler
China-universal-asset-management-co
Day-one-biopharmaceuticals-inc
Needham-company
Jpmorgan-chase-co
Nasdaq
Quintet-private-bank-europe
Exchange-traded-concepts
Goldman-sachs-group
Quest-partners

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender Sells 7,873 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) CEO Jeremy Bender sold 7,873 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $16.08, for a total transaction of $126,597.84. Following the completion of the sale, the chief executive officer now […]

Timessquare
New-york
United-states
Piper-sandler
Jeremy-bender
York-mellon-corp
Vanguard-group-inc
Goldman-sachs-group
York-state-common-retirement-fund
Timessquare-capital-management
Needham-company
Nasdaq

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.